Ningxia Zhongke Biotechnology Co., Ltd (SHA:600165)
China · Delayed Price · Currency is CNY 3.050
-0.150 (-4.69%)
May 21, 2026, 3:00 PM CST
SHA:600165 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 465.53 | 441.69 | 342.78 | 279.46 | 679.35 | 246.77 |
Other Revenue | 2.79 | 2.79 | 2.54 | 6.23 | 1.79 | 1.95 |
| 468.31 | 444.48 | 345.32 | 285.69 | 681.13 | 248.72 | |
Revenue Growth (YoY) | 21.56% | 28.72% | 20.87% | -58.06% | 173.86% | 108.80% |
Cost of Revenue | 633.97 | 646.21 | 478.88 | 419.51 | 634.69 | 387.14 |
Gross Profit | -165.66 | -201.73 | -133.57 | -133.82 | 46.45 | -138.43 |
Selling, General & Admin | 69.17 | 70.67 | 54.29 | 52.75 | 102.07 | 36.57 |
Research & Development | 41.79 | 38.54 | 12.48 | 13.87 | 25.51 | 20.21 |
Other Operating Expenses | 9.21 | 8.04 | 7.76 | 2.9 | 6.16 | 5.29 |
Operating Expenses | 123.16 | 120.25 | 74.74 | 68.35 | 133.85 | 61.79 |
Operating Income | -288.82 | -321.97 | -208.31 | -202.18 | -87.41 | -200.22 |
Interest Expense | -27.47 | -27.47 | -145.37 | -142.52 | -91.88 | -31.28 |
Interest & Investment Income | 341.14 | 341.14 | 0.02 | 34.36 | 35.67 | 40.5 |
Currency Exchange Gain (Loss) | -0.07 | -0.07 | 0.9 | 0.58 | 1.92 | -0.62 |
Other Non Operating Income (Expenses) | 8.56 | -0.11 | -11.6 | -0.61 | -0.41 | -0.04 |
EBT Excluding Unusual Items | 33.34 | -8.48 | -364.36 | -310.37 | -142.1 | -191.66 |
Gain (Loss) on Sale of Investments | - | - | -83.26 | - | - | - |
Gain (Loss) on Sale of Assets | 3.05 | 3.05 | -2.37 | 0.21 | -0.06 | 2.1 |
Asset Writedown | -142.9 | -110.76 | -106.56 | -185.07 | -23.66 | - |
Legal Settlements | -24.57 | -24.57 | -14.46 | -3.96 | - | - |
Other Unusual Items | -17.22 | -17.22 | -8.06 | -16.35 | 0.07 | 2.51 |
Pretax Income | -148.29 | -157.98 | -579.07 | -515.54 | -165.75 | -187.05 |
Income Tax Expense | 5.6 | 4.92 | -2.04 | -0.28 | 4.36 | 2.39 |
Earnings From Continuing Operations | -153.89 | -162.89 | -577.03 | -515.26 | -170.11 | -189.44 |
Minority Interest in Earnings | 63.27 | 72.52 | 38.12 | 50.55 | 28.62 | 23.35 |
Net Income | -90.62 | -90.38 | -538.91 | -464.71 | -141.48 | -166.09 |
Net Income to Common | -90.62 | -90.38 | -538.91 | -464.71 | -141.48 | -166.09 |
Shares Outstanding (Basic) | 1,845 | 1,614 | 685 | 684 | 683 | 683 |
Shares Outstanding (Diluted) | 1,845 | 1,614 | 685 | 684 | 683 | 683 |
Shares Change (YoY) | 169.93% | 135.68% | 0.05% | 0.13% | 0.00% | 1.35% |
EPS (Basic) | -0.05 | -0.06 | -0.79 | -0.68 | -0.21 | -0.24 |
EPS (Diluted) | -0.05 | -0.06 | -0.79 | -0.68 | -0.21 | -0.24 |
Free Cash Flow | -743.67 | -644.57 | -91.39 | -34.53 | -6.17 | -258.32 |
Free Cash Flow Per Share | -0.40 | -0.40 | -0.13 | -0.05 | -0.01 | -0.38 |
Gross Margin | -35.37% | -45.38% | -38.68% | -46.84% | 6.82% | -55.66% |
Operating Margin | -61.67% | -72.44% | -60.32% | -70.77% | -12.83% | -80.50% |
Profit Margin | -19.35% | -20.33% | -156.06% | -162.66% | -20.77% | -66.78% |
Free Cash Flow Margin | -158.80% | -145.02% | -26.47% | -12.09% | -0.91% | -103.86% |
EBITDA | -161.34 | -194.58 | -81.28 | -64.7 | 35.08 | -140.73 |
EBITDA Margin | -34.45% | -43.78% | -23.54% | -22.65% | 5.15% | -56.58% |
D&A For EBITDA | 127.48 | 127.39 | 127.03 | 137.48 | 122.48 | 59.49 |
EBIT | -288.82 | -321.97 | -208.31 | -202.18 | -87.41 | -200.22 |
EBIT Margin | -61.67% | -72.44% | -60.32% | -70.77% | -12.83% | -80.50% |
Revenue as Reported | 444.48 | 444.48 | 345.32 | 285.69 | 681.13 | 248.72 |
Advertising Expenses | - | 0.07 | 0.42 | 0.26 | 0.31 | 0.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.